Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages

  Kelly, Paul J ^a   Weiss, Stephanie E ^a   Sher, David J ^a   Perez Atayde, Antonio R ^b   Dal Cin, Paola ^a   Choueiri, Toni K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; PREDNISONE; SUNITINIB; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; BRAIN EDEMA; BRAIN METASTASIS; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CORTICOSTEROID THERAPY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLANK PAIN; GENE REARRANGEMENT; HUMAN; KIDNEY CARCINOMA; LETHARGY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STEROID THERAPY; VOMITING; WEAKNESS; ADOLESCENT; BRAIN TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDOLES; NEOPLASM METASTASIS; PYRROLES;

EID: 77957603470     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.8193     Document Type: Article

References (13)

1. US Food and Drug Administration: Sunitinib malate. http://www.fda.gov/ AboutFDA/CentersOffices/CDER/ucm129255.htm
2. Gore ME, Szczylik C, Porta C, et al: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 10:757-763, 2009
3. Patyna S, Peng J: Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer 4:21, 2006
4. Medioni J, Cojocarasu O, Belcaceres JL, et al: Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 18:1282-1283, 2007 (Pubitemid 47244377)
5. Negrier S: Case report 3: Sunitinib malate in patients with cerebellar metastases. Eur J Cancer 5:S32-S34, 2007 (suppl)
6. Helgason HH, Mallo HA, Droogendijk H, et al: Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol 26:152-154, 2008
7. Zwolak P, Jasinski P, Terai K, et al: Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer 44:2506-2517, 2008
8. Cuneo KC, Geng L, Fu A, et al: SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71:873-879, 2008 (Pubitemid 351749533)
9. Casneuf VF, Demetter P, Boterberg T, et al: Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: An experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol Rep 22:105-113, 2009
10. Yoon SS, Stangenberg L, Lee YJ, et al: Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 74:1207-1216, 2009
11. Kao J, Packer S, Vu HL, et al: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: Acute toxicity and preliminary response. Cancer 115:3571-3580, 2009
12. Hill KL Jr, Lipson AC: Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma. J Neurosurg 111:497-503, 2009
13. Kamoun WS, Ley CD, Farrar CT, et al: Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542-2552, 2009